Despite R&D Spending Growth at Pharma, Tool Shops Will Be Left in the Cold | GenomeWeb

This update serves to clarify a statement made by Margaret Flanagan of AstraZeneca. In an earlier version of the story, Flanagan was paraphrased as saying "There's nothing on the horizon" worth buying.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.